amp biosimilars AG / Key word(s): Change of Personnel
2015-04-28 / 07:30
amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as chairman of the Scientific Board
– Former head of global biopharmaceuticals at Boehringer Ingelheim
– Honorary Senator and professor at the University of Tübingen
– Experience in the development of numerous biosimilars and biopharmaceuticals
Hamburg, 28. April 2015 – amp biosimilars AG (ISIN: DE00A0SMU87), a company specializing in the development of high quality biosimilars, has named Professor Dr. Dr. Rolf G. Werner to head up the Scientific Board, effective immediately. In his new role, Professor Werner will serve as the “Chairman of the Scientific Board”.
Rolf G. Werner is a Professor of Industrial Biotechnology and an Honorary Senator at the Eberhard Karls University Tübingen. He is one of the world’s leading experts in research, development and production of pharmaceutical biotechnologies, with more than 35 years of industry experience in various leadership positions at Boehringer Ingelheim, including head of global biopharmaceuticals. The company’s more than 47,000 employees and revenues of EUR 13.3 billion in 2014 make Boehringer Ingelheim the largest research pharmaceutical company in Germany.
Prof. Werner’s scientific contributions include more than 180 publications, 20 patents and 15 scientific films. His work has been honored with the City of Vienna Prize for his outstanding contributions to science and by the administrative district of Hangzhou, China, where he was named a Hangzhou Qian Jiang Distinguished Expert.
“We are thrilled to have Professor Werner on our team,” says Dr. Marc W. Hentz, Chief Executive Officer of amp biosimilars AG. “His vast expertise with every aspect of the development and production of biotechnological materials and pharmaceuticals as well as his international network make him the ideal partner to help identify and commercialize biosimilar blockbusters.”
“It is nothing less than a moral obligation to help find affordable, efficient and safe high quality biosimilars that will give the general global populace the means for improved quality of life, and I am happy to be able to help in this regard,” says Professor Werner, Honorary Senator at the University of Tübingen.
The Scientific Board at amp biosimilars AG is currently composed of three members and supports management with the implementation of its global biosimilar development and commercialization strategy. In addition to its chairman, Prof. Werner, the Scientific Board includes Dr. Holger Ziehr and Dr. Xavier Luria. Dr. Ziehr, head of the Department of Pharmaceutical Biotechnology at the ITEM Fraunhofer Institute, has previously developed numerous biosimilars such as EPO, G-CSF and ß-interferon until the GMP production. Dr. Luria has been the Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA), where he coordinated international teams from the 28 EU member states in the regulatory evaluation of medical products.
About amp biosimilars AG:
2015-04-28 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.
Northern Data reports on course of business for July 2022 and expected total cryptocurrency production in 2022
Preliminary reported EBITDA EUR 50 million higher than reported on 30 June 2022. Northern Data expects finalization of audit 2021 financial statements in August 2022.
Get regular updates